CLPTM1L

Across TCGA pan-cancer cohorts, CLPTM1L mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of CLPTM1L’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where CLPTM1L mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CLPTM1L is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

LUAD, CCRCC, and LSCC are the cancer types where CLPTM1L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CLPTM1L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	+0.903	<.001	9	view →
CCRCC	Male	II,III,IV	+0.547	<.001	9	view →
LSCC	Female	II,III,IV	+0.649	<.001	8	view →
PDAC	Male	All	−0.833	<.001	6	view →
HNSC	Male	All	+0.305	<.001	4	view →
OV	All	All	+0.231	.049	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

CLPTM1L–LUAD

Open the LUAD breakdown →